Direct current ablation destroys multi-stage fibrosarcomas in rats

Area of Science:

• Oncology
• Immunology
• Medical Devices

Background:

• Direct current (DC) ablation is a promising technique for tumor targeting and immune stimulation.
• Widespread clinical adoption of DC ablation remains limited.
• This study investigated combining DC ablation with low-current pretreatment to enhance efficacy and assess immune response.

Purpose of the Study:

• Evaluate the impact of DC ablation, with and without low-current pretreatment, on tumor size and survival in a rat model.
• Assess potential immune system activation.
• Examine stimulation-related parameters.

Main Methods:

• Methylcholanthrene-induced fibrosarcoma tumors were established in 26 Fischer 344 rats.
• Four treatment groups were used: no treatment, placebo, high-current ablation, and low-current pretreatment followed by high-current ablation.
• Electrodes were placed at the tumor base, and treatments commenced when primary tumors reached 700 mm³.

Main Results:

• All control animals were euthanized by day 55 due to tumor growth.
• Tumors in all 16 treated rats disappeared within eight days, with two requiring retreatment.
• Low-current pretreatment did not significantly affect tumor disappearance or survival rates.

Conclusions:

• Direct current ablation demonstrated high efficacy in tumor destruction within this rat model.
• Slower growth of contralateral tumors suggests a potential systemic or immune-mediated effect.
• Further research is warranted to explore the immunomodulatory aspects of DC ablation.